US FDA’s ‘Narrow Path’ Squeezes Some Firms New To Sanitizer Space Under Enforcement Discretion
Executive Summary
Among firms entering the sanitizer space during COVID-19 pandemic, those adhering to FDA’s GMPs could remain in the market expected to reach $3.65 by 2025. Shook, Hardy and Bacon attorneys say companies should determine whether they realistically can follow FDA’s “narrow path” of regulation.